LAUSR

OBJECTIVES We aim to report the functional and oncological outcomes in men with localized prostate cancer who underwent individualized partial gland cryoablation of the prostate using validated quality of life instruments. METHODS We retrospectively reviewed our cryosurgery database between July 2003 and September 2019 for men who were treated with individualized partial gland cryoablation of the prostate at our tertiary care center. Baseline and periodic urinary and sexual function surveys were administered throughout the post-treatment period. RESULTS A total of 82 men were included in the study. Median follow-up was 28 months (IQR: 10.5 - 59.3 months). A total of 71 men underwent primary individualized partial gland cryoablation whereas 11 men underwent salvage partial gland ablation. Failure-free survival at 1 to 5 years was 98%, 89%, 84%, 75%, 75% in the primary therapy group, and 100%, 80% and 40% in the salvage group at 1 to 3 years, respectively. In the primary therapy group, all 71 patients remained free of pads at 3 months and throughout the follow-up period. Men who have undergone primary focal cryoablation had a higher post-treatment IIEF score, followed by men treated with primary hemi-cryoablation and primary subtotal cryoablation. AUA symptom scores decreased regardless of type of partial gland ablation performed, with subtotal ablation having the lowest score compared to hemiablation and focal cryoablation. No patient developed a fistula in the primary group and 1 (9%) patient developed a fistula in the salvage group. CONCLUSION Individualized partial gland cryoablation of the prostate is able to achieve excellent oncological and functional outcomes in select men with localized prostate cancer.